Clinical Trials Logo

Clinical Trial Summary

In this study,the investigators will evaluate participants that have clinical features associated with an increased risk of esophageal disorders.The investigators will also see if there is a positive association of esophageal disorders in men,40-60 with or without abdominal obesity in the diagnosis of the following diseases; Gastroesophageal reflux disease, Barrett Esophagus and Esophageal Adenocarcinoma. The investigators hypothesize that most obese patients referred for Esophagogastroduodenoscopy will exhibit esophageal disorders. Since currently the rates of obesity and adenocarcinoma of the esophagus have increased significantly over the past 15 years, the investigators hope to find biochemical markers (i.e. pro-inflammatory mediators) in the esophagus. The investigators hope these samples will lead us to a differential expression of molecular markers and inflammatory mediators in the varying degrees of esophageal disorder


Clinical Trial Description

Patients with elevated central adiposity have an increased risk of esophageal disorders; we will correlate central adiposity with advanced esophageal pathologies (BE and EAC). This will be done by comparing body mass and fat distribution to tissue abnormalities found by pathology review of EGD biopsy. It is anticipated that the group of men in this study will have an increased likelihood of histopathologic alteration, which we will fit into our scale (0-no inflammation, 1-inflammation or BE, 2-BE with dysplasia, and 3-carcinoma) according to the referral pattern at UAB's outpatient gastroenterology clinic.

At the molecular level, there is also a relationship between pro-inflammatory cytokines and obesity, which may contribute to esophageal disorder [28]. Metabolically active fat cells secrete cytokines exclusive to adipose tissue (adipokines, leptin/adiponectin) as well as the more classic signaling molecules, tumor necrosis factor alpha (TNF-α); interleukins (IL)-1, IL-6, IL-8, and IL-10; monocyte chemoattractant protein 1 (MCP-1); and macrophage inflammatory protein 1 (MIP 1) [29-33]. Obesity-triggered pro-inflammatory molecules may promote tissue injury, leading to metaplasia and dysplasia in BE and, subsequently, to carcinoma.

Thus, by measuring these pro-inflammatory markers in our prospective patient population, it will be determined if patients with elevated levels exhibit pathologic disorders in the esophagus and if the differential expression of these molecular markers correlates with degree of esophageal disorder. We will analyze samples collected from men for adipocytokines and for inflammatory mediators that are released with tissue injury. Additionally, we will examine molecular markers that correlate with more advanced esophageal disorders (BE with high grade dysplasia and EAC).

Persistent stimulation is needed to cause stepwise progression from the early stages of esophageal injury, to BE, to carcinoma. Since the molecular events that lead to this transformation are not known, our goal is to profile biopsy tissues collected from the prospective cohort of 60 men, analyzed by IHC for p53, Ki67, cyclin D1, IL-6, IL-8, Cox-2, DKK-1, CD44, leptin, and adiponectin. These molecules are known to be involved in transformation of normal esophageal epithelium to EACs via progression from metaplasia and BE to low-grade dysplasia and high-grade dysplasia. [34]. The clinical outcome measurements will be correlated with the levels of these molecules, determined by IHC, with metaplasia, degree of dysplasia in BE, and stage of EAC. For BE tissues, there is a correlation between the extent of p53 staining and aggressive clinical features. Our preliminary findings on six BEs, selected from the patient population at UAB, indicate that a high proportion of p53 staining directly correlates with high-grade lesions ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02476513
Study type Observational
Source University of Alabama at Birmingham
Contact
Status Completed
Phase N/A
Start date February 2014
Completion date July 2016

See also
  Status Clinical Trial Phase
Recruiting NCT05054933 - Ultrasound Capsule Endoscopy for Esophagus Examination N/A
Completed NCT04090554 - Cytosponge™ Feasibility Study in Tanzania N/A
Active, not recruiting NCT03962179 - Feasibility and Efficacy of a Combination of a SEMS and Vacuum Wound Treatment (VACStent) N/A
Completed NCT03549494 - Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction Phase 2
Recruiting NCT04481100 - CCRT With Itraconazole in Locally Advanced Squamous Esophageal Cancer Phase 2
Completed NCT03859557 - The Evaluation of Patients With Esophageal and Foregut Disorders With WATS (Wide Area Transepithelial Sample With 3-Dimensional Computer-Assisted Analysis) vs. 4-Quadrant Forceps Biopsy
Completed NCT00977678 - Drop in Gastroscopy - Experience After 9 Months N/A
Recruiting NCT04068480 - Esophageal and Gastric Diseases With Robotically Controlled Magnetic Capsule Endoscopy
Completed NCT00874263 - Confocal Probe-based Endoscopic Imaging, Colorectal Cancer, Gastrointestinal (GI) Pathologies N/A
Terminated NCT00442507 - Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction Phase 2
Recruiting NCT03832959 - Esophageal Damage Protection During Pulmonary Vein Ablation. Pilot Study. N/A
Withdrawn NCT02569073 - Investigation of Cannabinoid Receptor Agonist Dronabinol in Patients With Functional Chest Pain Phase 4
Recruiting NCT05252078 - Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients Phase 2
Recruiting NCT00260585 - Esophageal Cancer Risk Registry
Completed NCT03187314 - Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer Phase 2
Recruiting NCT05004155 - Twenty Four Hour Ambulatory pH & Impedance Testing: Normative Data for Indian Population
Recruiting NCT05469152 - Detachable String Magnetically Controlled Capsule Endoscopy for Follow-up of Patients With Esophageal Diseases N/A
Recruiting NCT05877300 - Safety and Feasibility Study of the CELLSPAN Esophageal Implant (CEI) in Patients Requiring Short Segment Esophageal Replacement Phase 1
Recruiting NCT03267355 - Indications and Outcomes of Endoscopic Ultrasound in Tanta N/A
Recruiting NCT05311787 - The Strategy of Implementation of the ERAS Protocol After Esophageal Surgery N/A